share_log

VBI Vaccines Announces Presentation Of Physician-Initiated Compassionate Use Data Of 3-Antigen Hepatitis B Vaccine At 2022 International HBV Meeting; Presentation Was Monday, Sept. 19

VBI Vaccines Announces Presentation Of Physician-Initiated Compassionate Use Data Of 3-Antigen Hepatitis B Vaccine At 2022 International HBV Meeting; Presentation Was Monday, Sept. 19

VBI疫苗公司宣佈在2022年國際乙肝會議上展示醫生發起的3-抗原乙肝疫苗的同情使用數據；展示時間為9月1日星期一。19個
Benzinga Real-time News ·  2022/09/21 08:06

VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI's 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.

VBI疫苗公司(納斯達克代碼：VBIV)(VBI)是一家以免疫學為動力的生物製藥公司，致力於強有力的疾病預防和治療。該公司今天宣佈，9月19日在法國巴黎舉行的2022年國際乙肝會議上，醫生發起的同情使用VBI3抗原乙肝疫苗的數據在2022年法國巴黎國際乙肝會議上公佈。

Poster Presentation Details

海報展示詳情

  • Title: Therapeutic vaccination of chronically HBV infected patients with low-level of HBsAg using a combination of a third generation PreS/S vaccine (Sci-B-Vac) and a nucleoside analogue
  • Session: Poster Session I
  • Date: Monday, September 19, 2022
  • Presenter: Hedwig Roggendorf, M.D., Institute of Molecular Immunology and Experimental Oncology, University Hospital Rechts der Isar, Technical University of Munich
    • Event Website:
  • 標題：使用第三代PreS/S疫苗(SCI-B-VAc)和核苷類似物聯合接種低水平HBs慢性感染患者的治療性疫苗
  • 會話：招貼會I
  • 日期：2022年9月19日(星期一)
  • 主講人：德國慕尼黑工業大學分子免疫學和實驗腫瘤學研究所
    • 活動網站：
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論